C20/20 Innovation Hub

What C20/20 Innovation Hub does

C20/20 Innovation Hub is a privately held Partner Research Organization (PRO) embedded within McMaster University in Hamilton, Ontario, Canada. It specializes in the development and commercialization of ophthalmic bioengineered technologies and drug delivery systems, serving as a translational bridge between early-stage academic chemistry and preclinical validation for ophthalmic therapeutics. The organization describes itself as the only PRO in Canada with particular expertise in the ophthalmic space.

Its core offering is an integrated suite of wet-lab research services. Materials Development covers the design, synthesis, and characterization of novel ophthalmic biomaterials. In Vitro Testing provides drug delivery assays and characterization for ophthalmic therapeutic candidates, while Preclinical Research delivers non-GLP preclinical validation. Differentiated offerings include IMED (Immune Modulation for Enhanced Delivery), a specialized service targeting immune modulation strategies in ophthalmic drug delivery, and C20/20+, an enhanced R&D add-on. Wrapping these are Equipment Access to state-of-the-art laboratory infrastructure and Support Services covering grant writing, project management, and business development. Underlying capabilities include chemistry, synthesis, material design, assay development, and preclinical study execution, all leveraging McMaster University's facilities and an interdisciplinary team led by Executive Director Fran Lasowski.

The business model is a B2B professional services contract research model. Revenue is generated through customized research engagements with private sector ophthalmic pharmaceutical and medical device companies and with academic research teams, using direct enterprise engagement rather than a published pricing model. Geographic scope is declared as global despite a single Hamilton, Ontario facility, and the go-to-market relies on the institutional McMaster brand, direct outreach, and the corporate website. No public pricing, customer logos, funding history, revenue figures, or patent portfolio are disclosed in the available data.

Name

C20/20 Innovation Hub

Legal name

C20/20 Innovation Hub

Website

https://c2020hub.ca

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

C20/20 Innovation Hub is a Partner Research Organization embedded at McMaster University in Hamilton, Ontario, providing contract research and development services in ophthalmic biomaterials, in vitro drug delivery testing, and non-GLP preclinical validation to private sector and academic clients.

Ownership category

akta.pro rank

Product category

Ophthalmic Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Ophthalmic research services
• Biomaterials development
• Drug delivery testing
• Preclinical validation services
• Translational research

Headquarters

HQ city

Hamilton

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Research Services: Providing contracted research and development services to private sector and academic clients including materials development, in vitro testing, and preclinical validation

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

C20/20 Innovation Hub is a Partner Research Organization embedded at McMaster University that provides contracted research and development services for ophthalmic technologies. Its offerings span materials development, in vitro drug delivery testing and characterization, non-GLP preclinical validation, and the specialized IMED (Immune Modulation for Enhanced Delivery) program, supplemented by equipment access and commercialization support services such as grant writing, project management, and business development.

Product overview

C20/20 Innovation Hub is a Partner Research Organization (PRO) offering a integrated suite of services for ophthalmic technology development and commercialization. The portfolio includes core research services (Materials Development, In Vitro Testing, Preclinical Research, and IMED: Immune Modulation for Enhanced Delivery) supplemented by Equipment Access and Support Services (grant writing, project management, business development). The organization operates from McMaster University and partners with both private sector and academic teams to provide customized solutions from early-stage chemistry through preclinical validation.

Differentiator

Problem solved

Functional benefit

Brands

• C20/20+: Service offering under the C20/20 Innovation Hub brand
• IMED: Immune Modulation for Enhanced Delivery

Products and services

• Materials Development Contracted research service providing development and design of novel biomaterials for ophthalmic applications, ranging from early-stage chemistry through synthesis and material design, for private sector and academic teams.
• In Vitro Testing Contracted laboratory service providing in vitro drug delivery testing, assays, and characterization for ophthalmic therapeutic candidates.
• Preclinical Research Contracted research service providing non-GLP preclinical validation for ophthalmic technologies and therapeutic approaches.
• C20/20+ Enhanced contracted research and development service offering within the C20/20 portfolio, providing advanced capabilities beyond core offerings.
• IMED: Immune Modulation for Enhanced Delivery Specialized contracted research service focusing on immune modulation strategies to enhance drug delivery in ophthalmic applications.
• Equipment Access Provision of state-of-the-art laboratory equipment at McMaster University to support client research project needs.
• Support Services Contracted support services including grant writing, project management, and business development to facilitate research partnerships and commercialization of ophthalmic technologies.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• McMaster UniversitycoreStrategic or Co-development PartnerC20/20 Innovation Hub is embedded within McMaster University, utilizing world-class facilities and academic expertise. This strategic partnership provides access to state-of-the-art equipment, interdisciplinary research teams, and academic resources essential for ophthalmic technology development and commercialization.

Scale indicators1 record

Recent moves1 record

Expansion highlights4 records

Direct peers

• Iris Pharma: French preclinical CRO dedicated exclusively to ophthalmology, offering preclinical models, drug delivery evaluation, and regulatory support. Directly comparable to C20/20 as a domain-specialized ophthalmic research services provider.
• Absorption Systems: Preclinical CRO specializing in drug absorption, pharmacokinetics, and drug-device combination testing. Overlaps with C20/20's in vitro drug delivery testing and biomaterials development capabilities.
• MD Biosciences: Preclinical CRO offering efficacy and translational models, including ocular inflammation and ophthalmic disease models. Comparable as a preclinical-focused CRO with adjacent therapeutic area expertise.
• PharmOptima: Ophthalmic preclinical CRO offering in vivo ocular efficacy, pharmacokinetics, and toxicology services. Comparable as a dedicated ophthalmic preclinical services competitor.
• Ocular Services Inc (OSI): US-based ophthalmic-focused preclinical CRO providing ocular pharmacokinetics, efficacy, and safety studies for drug and device developers. Comparable to C20/20 in niche ophthalmic preclinical services.

Broad incumbents

• WuXi AppTec: Global CRO/CDMO with preclinical, biologics, and ophthalmic testing capabilities across multiple geographies. Comparable as a full-service alternative that competes for the same ophthalmic R&D budgets.
• Charles River Laboratories (Preclinical): Large global CRO with extensive preclinical ophthalmic capabilities alongside broader drug discovery and development services. Comparable as a scaled alternative clients may choose instead of C20/20.

Others

• McMaster Innovation Park: Research and commercialization park affiliated with McMaster University housing biotech startups and service organizations. Comparable as the host ecosystem where C20/20 sits and which channels talent and tenant clients to the hub.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/c202012

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C20/20 Innovation Hub